CJC-1295 with DAC
Boosts growth hormone for deeper sleep
- Muscle Growth/Recovery
- Fat Loss
- Anti-Aging
- Sleep Improvement
Limited human safety data—most knowledge extrapolated from GH pharmacology and community reports Extended half-life means side effects may persist longer than with shorter-acting secretagogues Contraindicated in active malignancy—GH/IGF-1 may promote tumor growth Use caution in prediabetics or diabetics—monitor glucose closely Long-term effects on tumor risk, organ growth, and metabolic health are unknown
Mechanism of Action
CJC-1295 with DAC is a synthetic analog of growth hormone-releasing hormone (GHRH) that binds to GHRH receptors on pituitary somatotroph cells, stimulating the release of endogenous growth hormone. The Drug Affinity Complex (DAC) modification allows the peptide to bind to serum albumin, extending its half-life from minutes to approximately 6-8 days, enabling sustained GH elevation rather than pulsatile release. Key Pathways: GHRH receptor activation on anterior pituitary, GH/IGF-1 axis amplification, Albumin binding via DAC for extended half-life The sustained elevation of growth hormone leads to increased IGF-1 levels, which theoretically promotes protein synthesis in muscle tissue, enhanced lipolysis, and improved tissue repair. The extended half-life means less frequent dosing compared to non-DAC variants, though this same property creates continuously elevated GH rather than natural pulsatile patterns, which may have implications for efficacy and desensitization.
Common Dose Reference Ranges
Educational reference ranges only — discuss actual dosing with a qualified healthcare provider.
Full CJC-1295 with DAC protocols — frequency, timing, cycle length, reconstitution & research
- Water retention/edema
- Injection site reactions
- Flushing/warmth sensation
- Headache
- Fatigue/lethargy
- Tingling/numbness in extremities
- Joint pain/stiffness
- Potential cortisol elevation